How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks
Huberman Lab Podcast Recap
Published:
Duration: 2 hr 46 min
Guests: Robin Carhart-Harris, Dr. Matthew Johnson
Summary
This episode discusses psilocybin's potential to rewire the brain, offering therapeutic benefits for conditions like depression and addiction. It also touches on the associated risks, particularly for individuals with certain mental health predispositions.
What Happened
Psilocybin, a psychedelic compound found in certain mushrooms, modifies consciousness by mimicking serotonin and activating the serotonin 2A receptor. This leads to increased neuroplasticity, particularly in brain areas involved in memory and perception, contributing to its therapeutic potential.
Researchers are exploring psilocybin for its effectiveness in treating depression, anxiety, alcohol use disorder, and OCD. Clinical trials have shown that psilocybin can outperform traditional SSRIs in treating major depression, with significant relief observed weeks after a single dosing session.
The compound is converted to psilocin in the body, which is responsible for its psychoactive effects. Psilocybin increases communication across different brain regions, reducing the modularity and hierarchical organization of the brain, which may underlie its therapeutic effects.
Psilocybin therapy involves guided sessions where set and setting play crucial roles in ensuring safety and efficacy. Participants usually experience visual hallucinations due to high serotonin 2A receptor expression in the visual cortex, and music significantly influences the emotional experience during sessions.
Studies show that ego dissolution and mystical experiences during psilocybin sessions correlate with positive therapeutic outcomes. However, high levels of anxiety can hinder these benefits, highlighting the importance of managing anxiety through techniques like the physiological sigh.
Psilocybin is not advised for individuals predisposed to psychotic disorders or those under 25, as their brain development is not yet complete. The compound remains a Schedule 1 drug in the U.S., though it has been decriminalized in some areas, allowing for more research into its potential benefits.
Researchers like Robin Carhart-Harris from UCSF have documented increased brain connectivity during psilocybin sessions. This expanded connectivity persists even after the effects of the psychedelic wear off, suggesting long-term changes in brain function.
Dr. Matthew Johnson from Johns Hopkins incorporates tools like real-time respiration monitoring to manage anxiety during psilocybin therapy. These interventions help participants navigate the challenging aspects of the psychedelic experience, enhancing therapeutic outcomes.
Key Insights
- Psilocybin primarily affects the serotonin 2A receptor, leading to increased neuroplasticity in brain regions related to perception and memory. This effect is thought to contribute to its potential therapeutic benefits for various psychiatric disorders.
- Clinical trials indicate that psilocybin can provide significant relief from major depression, with 25 mg doses showing stable results up to 12 weeks post-session. However, higher doses correlate with a greater risk of adverse events such as headaches and suicidal ideation.
- Psilocybin therapy often involves guided sessions with specific attention to set and setting, enhancing the therapeutic potential while minimizing risks. Music and other external factors are carefully controlled to shape the emotional and sensory experience during these sessions.
- Studies have shown that psilocybin increases connectivity between brain regions, reducing hierarchical organization and promoting lateral communication. This expanded connectivity remains after the acute effects wear off, suggesting lasting changes in brain function.